In vitro dermal absorption and metabolism of D&C red no. 17 in human and porcineskin.
D&C red no. 17 is approved for use in externally applied drug and cosmetic applications, in amounts consistent with good manufacturing practice. Concerns about the safety of the color additive (1-[4-phenylazophenylazo]-2-napthol (PAN) is the primary color constituent) have been raised due to potential metabolic cleavage of PAN to yield 4-aminoazobenzene. (14)C-PAN was applied in a commercially available suntan vehicle containing D&C red no. 17 to viable porcine and non-viable (cadaver) human skin in flow-through diffusion cells. At the end of 24 h, unabsorbed material was removed from the skin and some cells were allowed to continue for an additional 48 h. In human skin, 0.07% and 0.17% of the applied dose were absorbed into the receptor fluid after 24 and 72 h, respectively. At the end of 24 h, 12.5% of the applied dose remained in the skin, which did not decrease at 72 h. When PAN was applied to viable porcine skin for 24 h, 0.3% of the applied dose was absorbed and 12.7% remained in the skin. Additional studies to simulate short-term exposure were completed with PAN applied to the skin for only 15 min, and absorption was determined for 24 and 72 h. These studies in human cadaver skin found 0.02% and 0.08% of the applied dose in the receptor fluid after 24 and 72 h, respectively. Viable porcine skin studies with the 15-min application resulted in receptor fluid values of 0.1% of the applied dose after 24 h. Lipophilic receptor fluids composed of the non-ionic surfactant Volpo 20 at wt% concentrations of 1%, 3%, or 6% in water did not increase partitioning of PAN from the skin into the receptor fluid. No metabolism of PAN was found in viable porcine skin when examined by HPLC. In conclusion, skin absorption of PAN from a commercially available suntan product was low.
Yourick
Jeffrey
J
Office of Cosmetics and Colors, US Food and Drug Administration, 5100 Paint Branch Parkway, College Park, MD 20740, USA.
Sasik
Camille
C
Bronaugh
Robert L
RL
D000279:Administration, Cutaneous; D000818:Animals; D001391:Azo Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology; D003358:Cosmetics / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D009284:Naphthols / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology; D012867:Skin / Q000187:drug effects* / Q000378:metabolism*; D012869:Skin Absorption / Q000187:drug effects*; D013552:Swine
C525114:1-(phenylazophenylazo)-2-naphthol; D001391:Azo Compounds; D003358:Cosmetics; D009284:Naphthols